PRVB News and Press, Provention Bio Inc. From 06/13/19

DryShips (NASDAQ: DRYS ) +26%  after merger offer . More news on: DryShips Inc., Red Robin Gourmet Burgers, Inc., RH, Stocks on the move, Read more ...

OLDWICK, N.J. , June 13, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019 . The termination results from an assessment by the Company's management that current ma...

June 11, 2019 Palm Beach, FL – June 11, 2019 – Recent reports by industry specialists show that the Atopic Dermatitis Drugs Market Size Worth $6.41 Billion By 2022, exhibiting a CAGR of 6.6% during the forecast period. This is an increase from the 2016 market reven...

Jaguar Health (NASDAQ: JAGX ) +56%  as its subsidiary receives preclinical services funded by the National Institute of Allergy and Infectious Diseases. More news on: Jaguar Health, Inc., NovaBay Pharmaceuticals, Inc., Motus GI Holdings, Inc., Stocks on the move, Read more ... ...

OLDWICK, N.J. , June 10, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered underwritten public offering of 5,500,000 shares of...

PRVB stock in on fire and skyrockets as much as 300% after Provention Bio Inc (NASDAQ:PRVB) announced positive outcomes from its trial of teplizumab, its lead candidate. PRVB stock Jumps Big New Jersey-based Provention Bio, which is engaged in intercepting and treating diseases related ...

Gainers:  Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) ...

Provention Bio (NASDAQ: PRVB ) +170%  on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more ...

Thinly traded micro  cap Provention Bio (NASDAQ: PRVB ) rockets  176%  premarket on robust volume in reaction to its announcement of positive trial data on lead candidate teplizumab (PRV-031), in Phase 3 development for the interception of type 1 diabetes (T1D). The results ...

OLDWICK, N.J. , June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National Institutes of Health (NIH)-sponsored "At-Risk" Study...